



NEPHRO CARE INDIA LIMITED

(FORMERLY KNOWN AS NEPHRO CARE INDIA PRIVATE LIMITED)

CIN: L85100WB2014PLC202429

Regd. Office- Flat No-1 JC-18, 5th Floor Sec-III, Saltlake, Bidhan Nagar,

Sai Complex, North 24 Parganas, Kolkata - 700106, West Bengal, India.

Web: <https://www.nephrocareindia.com/>

Email id: cs@nephrocareindia.com

Contact: 080170 10197

Date: 17/07/2025

To

The Manager – Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051

Symbol: **NEPHROCARE**

Dear Sir/ Madam,

Subject: Intimation regarding media coverage on exploring opportunities for Bangladesh healthcare joint venture

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Nephro Care India Limited (“Company”), a Kolkata-based multi-specialty healthcare company, is exploring opportunities for entering into a Joint Venture Agreement in Bangladesh.

During an interaction with the media personalities, the same was discussed and subsequently published in a newspaper article. A copy of the said article is attached for your reference and records.

For Nephro Care India Limited

SOUGATA Digitally signed by
SOUGATA SENGUPTA
SENGUPTA Date: 2025.07.17
15:12:08 +05'30'

Sougata Sengupta
Company Secretary &
Compliance Officer

India Limited (NLCIL), allowing the Navratna PSU to invest 7,000 crore in its wholly owned subsidiary, NLC India Renewables Limited (NRL), bypassing existing investment norms applicable to Central Public Sector Enterprises (CPSEs).

This strategic move exempts NLCIL from the requirement of prior approval

the decision provides greater financial and operational flexibility to NLCIL and its green energy arm, NRL.

The investment aimed at fast-tracking NLCIL's renewable energy ambitions, with plans to ramp up its capacity from the current 2 GW to 10-11 GW by 2030 and 32 GW by 2047.

The initiative is in line

with the government's Net Zero emissions by 2070.

At present, NLCIL operates seven renewable energy projects with a combined capacity of 2 GW, either operational or nearing commercial launch.

These assets will be transferred to NRL following the cabinet approval. NRL is expected to emerge as NLCIL's flagship platform for scaling green energy oper-

ations will not only reinforce India's leadership in clean energy transition but also help reduce dependence on fossil fuels, cut coal imports, and enhance the reliability of 24x7 power supply.

Additionally, the move is projected to create substantial employment during the construction and operational phases, supporting local communities and inclusive economic growth.

schemes, according to regulatory filings posted on SEBI's official website.

Io BlackRock is a joint venture between the Mumbai-based Reliance Industries, through its subsidiary IIF Financial Services and BlackRock, which is one of the world's largest asset managers.

The 50:50 joint venture was first announced in July 2023 and received SEBI approval to start a mutual

fund (MF) business in late May of this year. Since then, Io BlackRock has gone on to receive approval to operate as an investment adviser and to commence operations as a brokerage firm.

SEBI's latest approval in the four mutual fund schemes sets the stage for Io BlackRock to further expand its footprint in India's growing passive mutual fund space.

The four approved schemes are IoBlackRock

Nifty Midcap 150 Index Fund, IoBlackRock Nifty Next 50 Index Fund, IoBlackRock Nifty Smallcap 250 Index Fund and the IoBlackRock Nifty 8-13 yr G-Sec Index Fund.

The last mentioned mutual fund will track the performance of medium-to-long-term government securities (gilts) in the 8-13 year maturity range. The IoBlackRock Nifty 8-13 yr G-Sec Index Fund is aimed at fund-

been structured as index funds and will only offer direct plans with growth options. All four approved schemes are structured with no exit loads, minimum application amounts as low as Rs 500, and standardised asset allocations in line with SEBI norms.

The new funds will open for subscription during a New Fund Offer (NFO) period lasting between three and 15 calendar days, as mandated by the SEBI, though exact dates are yet to be announced.

Deepak Parekh-backed Nephro Care flags off B'desh healthcare venture with PROBE, despite unrest

RITWIK MUKHERJEE
KOLKATA, 16 JULY

Dr Pratim Sengupta (photo), founder of Nephro Care India Pvt Ltd.

The social and political unrests in Bangladesh notwithstanding, Deepak Parekh-backed Kolkata-headquartered multi-specialty healthcare provider in East India, Nephro Care India Limited (NLCIL), flagged off its Bangladesh venture jointly with PROBE Bangladesh, a leading diagnostic chain in Bengal, Tripura and Bangladesh. Although this may not be the best time to launch this initiative, the two healthcare providers decided to roll-out this initiative, which had been hanging fire for quite some time now.

As part of the new joint initiative, Nephro Care would offer high-end diagnostic and other healthcare facilities through PROBE to patients in Bangladesh. PROBE has its wings even spread all across Bangladesh, said the doctor-turned-entrepreneur

Nephro Care. Vivacity and PROBE will work in tandem to strengthen its healthcare operations in Bangladesh and take it to a meaningful level. The ultimate objective is to ensure that the patients from the neighbouring country do not have to travel to India for every little problem and get themselves treated in their own country," said Biplob Sengupta, Director, Vivacity Hospital.

Nephro Care was founded in the year 2014 by one of



the leading nephrologists in India, Dr. Pratim Sengupta, in Kolkata, with the objective of providing comprehensive

medical services for renal patients. With over 20 years of active clinical experience, Dr. Sengupta, has successfully

performed more than 1,000 kidney transplants till now and is a pioneer in holistic renal care through a combination of clinical intervention, yoga and lifestyle support.

Besides the Bangladesh venture, Nephrocare is also rolling out another novel initiative called "Sampark" coinciding with the first anniversary of its 100-bed multi-specialty hospital, Vivacity at Madhyamgram in the northern fringes of the city, said Dr Sengupta. "Sampark" aims at reaching out to the community and offering free-of-cost healthcare guidelines, awareness and facilities.

"Our well-trained healthcare personnel will reach out to 10,000 people in the first phase of the programme and guide them about various dos and don'ts and will also offer them various healthcare facilities doorstep. Our teams have already reached out to

1700 people. We are well on target. This is our modest endeavour to give back to the society," said Dr Sengupta.

Nephro Care India Limited operates on a multidimensional patient engagement framework comprising programs and facilities such as Mukti, Home Dialysis, Home Care and Diagnostics.

While Mukti takes care of the overall well-being of the patient and improves the quality of life through a blend of modern medicine and ancient yoga wisdom, Home Dialysis offers dialysis at the comfort of homes to CKD patients who are unable to visit the dialysis centres, and "Home Care" services ensure clinical & lifestyle support beyond clinics to take care of all collateral medical needs of the patients.

Significantly, the reported prevalence of CKD in different regions in India ranges from 1 per cent to 13 per cent,

and recently, data from the International Society of Nephrology's Kidney Disease Data Center Study reported a prevalence of 17 per cent of the population. The etiology of CKD varies considerably throughout India. Parts of the states of Andhra Pradesh, Odisha, and Goa have high levels of CKD of unknown etiology (CKDu), which is a chronic interstitial nephropathy with insidious onset and slow progression, said Dr Sengupta.

Another way of looking at the gravity of the situation is that more than 1.3 billion people in India are served by 1850 nephrologists, who are unequally distributed but mostly concentrated in urban centers.

Nephrology training positions are inadequate to grow the workforce, and the situation is worsened by "brain drain" to developed countries.

Like other developing

countries, India has unique situations and challenges that influence early diagnosis and management of CKD. Facilities and expertise available in different parts of the country are unequally distributed. Prevention and early detection of CKD mandate involvement of physicians at all levels. Most patients with CKD can be managed by their primary physicians with timely nephrology referrals.

But unfortunately, they are not. The Indian Society of Nephrology modules should increase competence and lead to uniformity of delivered care. Initiatives, such as governmental provision of affordable and easily accessible RRT (where available), drastic reduction in commercial transplantation, and increasing deceased donor transplants, are improving care of patients with End-stage kidney disease (ESKD).